WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

Picture it: A marketing leader at a mid-sized financial services firm is finalizing next year's budget. Instead of spending days browsing multiple vendor websites, analyst PDFs, and peer reviews, she ...

International Business Machines Corporation stock plunges; downgrade IBM to Hold as Anthropic's Claude Code threatens ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...

SEO has historically been an exercise in reverse-engineering algorithms. Keywords, links, technical compliance, repeat. But that model is being reimagined. Today, visibility is earned through trust, ...

The Pima County Sheriff’s Office didn’t immediately launch a high-tech aircraft at the start of the search for Savannah Guthrie’s missing mother, possibly hurting the investigation, according to a ...

KNOXVILLE, Tenn. — Officials with Zoo Knoxville said Dolly, the giant reticulated python, got a comprehensive health evaluation for the first time in five years. Dolly got a full physical assessment, ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up for Dispatches, a newsletter that spotlights wrongdoing around the country, to receive our stories in your inbox every ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...